高级检索

钇-90微球选择性内放射治疗在肝细胞癌降期转化中的研究进展

Research progress of Yttrium-90 microsphere selective internal radiation therapy in downstaging and conversion of hepatocellular carcinoma

  • 摘要: 中国肝细胞癌(hepatocellular carcinoma,HCC)的发病率和死亡率均位居世界前列,造成了沉重的社会负担。肝切除术和肝移植手术是HCC根治性治疗的主要手段,但多数患者在初诊时已无法满足手术条件。钇-90微球选择性内放射治疗(Yttrium-90 microsphere selective internal radiation therapy,90Y-SIRT)具有强效缩瘤、增大余肝、消退门静脉癌栓、改善患者生活质量等优势,可安全有效地应用于HCC的转化、降期以及手术的桥接治疗,帮助患者重获根治性治疗的机会,并降低术后复发率。本综述主要阐述90Y-SIRT在此领域的临床应用及研究进展。

     

    Abstract: The incidence and mortality of hepatocellular carcinoma (HCC) in China are among the highest in the world, imposing a heavy social burden. Liver resection and liver transplantation are the primary radical treatments for HCC, although most patients are no longer able to meet the surgical requirements at initial diagnosis. Yttrium-90 microsphere selective internal radiation therapy (90Y-SIRT) has the advantages of shrinking tumors, enlarging residual liver, regressing portal vein tumor thrombus and improving the quality of life, which can be used for conversion, downstaging and bridging therapy for HCC before surgical treatment, enabling patients regain the chance of radical treatment and reducing the postoperative recurrence rate. This review focuses on the clinical application and progress of 90Y-SIRT in this field.

     

/

返回文章
返回